Exelixis, Inc. (EXEL)
70
  • CONTENT
  • SOURCES
Exelixis Cabozantinib Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:EXEL)
Exelixis reports data from COSMIC-021 trial of Cabozantinib. Agios reports final overall survival data for Tibsovo.
Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study | Health
"There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston. He noted that the oncology community is already familiar with both drugs and that the combination demonstrated positive results on all the study's goals.
Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study
Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday. The drug combination also doubled
Exelixis, Inc.'s (EXEL) CEO Mike Morrissey at BofA Global Healthcare Conference (Transcript)
Exelixis, Inc. (NASDAQ:EXEL) BofA Global Healthcare Conference September 16, 2020, 12:35 pm ET Executives Mike Morrissey - President, Chief Executive Officer Analysts Jason Gerberry - Bank of America Merrill Lynch Presentation Jason Gerberry All right.
Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics today announced new preclinical data that support the continued development of ICON-2, an ADC comprised of an anti-Tissue Factor (TF) antibody and Zymeworks’ proprietary linker-payload, for the treatment of diverse solid tumors. Exelixis has an exclusive option and license agreement for ICON-2 in oncology indications under its May 2019 agreement with Iconic Therapeutics, which d
Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an investor briefing to discuss data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The online-only event will be held following the closing of the Congress’ sessions on Saturday, September 19, 2020, beginning at 22:00 (10:00 p.m.) CEST / 4:00 p.m. EDT / 1:00 p.m. PDT. During the briefing, Exelixis management and invited guests from the clinical community will discu
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in September: Morgan Stanley 18th Annual Global Healthcare Conference: Exelixis is scheduled to present at 3:30pm EDT / 12:30pm PDT on Tuesday, September 15, 2020. BofA Securities Global Healthcare Conference 2020: Exelixis is scheduled to present at 5:35pm BST (British Summer Time) / 12:35p
Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
ALAMEDA, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and NBE-Therapeutics today announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific conjugation and novel payloads. The agreement comes as Exelixis continues to build out its pipeline behind CABOMETYX® (cabozantinib), its flagship product that is now
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Exelixis (EXEL) submits a supplemental new drug application to the FDA seeking approval of Cabometyx in combination with Opdivo for the treatment of advanced renal cell carcinoma.
Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell Carcinoma
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) for patients with advanced renal cell carcinoma (RCC). “We are excited to complete our first regulatory submission for CABOMETYX in combination with an immune-checkpoint inhibitor based on the positive results from the CheckMate -9ER phase 3
Exelixis (EXEL): market overreacted? What's the stock forecast?
Exelixis, Inc. (NASDAQ: EXEL) stock is down almost 15% today after the company reported that its colorectal cancer drug that was tested in combination with Roche's Tecentriq, and the combo failed study goals. What is the EXEL price forecast?
Follow Us